Immunovant Inc IMVT

Immunovant recently reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, where the drug did not achieve statistical significance on the primary CLASI-A endpoint at Week 12, leading the company to halt development for this indication. Despite observing numerical trends favoring IMVT-1402 and better responses in patients with deeper IgG reductions, Immunovant concluded that the combination of these data and a competitive treatment...

Immunovant (IMVT) just told the market that its proof-of-concept Phase 2b trial for IMVT-1402 in cutaneous lupus erythematosus missed the primary efficacy goal, and the program in this indication is being discontinued. The mixed trial outcome lands at a sensitive moment for Immunovant. The share price is US$33.49 after a 1-day share price return of 0.57%, yet the 7-day share price return is down 9.92% and the 30-day share price return is down 18.71%. This hints that recent traders have been...

Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program. Gline said Roivant recently received a

We all have bad days. Immunovant, Inc. (NASDAQ:IMVT) had its latest bad day on September 23 after a clinical-trial setback, sending the shares lower. The company reported that its Phase 2b proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve the primary endpoint. The study failed to show a statistically significant difference […]

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo.

Immunovant halts development of its lead drug candidate, imeroprubart, in skin lupus following a trial miss.

Immunovant is discontinuing development of IMVT-1402 in cutaneous lupus but will continue to develop the therapy for several other autoimmune diseases.

Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus.

Immunovant (NASDAQ:IMVT) shares fell 6% on Monday after the company reported that a proof-of-concept study evaluating IMVT-1402 in cutaneous lupus erythematosus did not meet its primary endpoint. The trial did not achieve statistical significance on its primary endpoint, which measured the percentage change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score at Week 12.

Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140

Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140

Immunovant has delivered very strong long term returns, and that kind of share price journey naturally raises the question of whether the current valuation still lines up with the company’s book value. With fresh attention on its autoimmune drug programs, investors are asking how much of that story is already embedded in the balance sheet metrics. Over the past 5 years, Immunovant has returned 337.4%, which puts a lot of weight on whether the underlying equity on its balance sheet can...

Immunovant (IMVT) has drawn fresh attention after recent trading left the stock around $37.36, with short term moves weaker but a strong total return profile over the past year and beyond. Recent trading tells a mixed story for Immunovant. Short term share price momentum has faded, with the stock down 4.8% over the past week and 10.7% over the past month. However, the 90 day share price return of 11.2% and 1 year total shareholder return of 140.6% show that longer term holders have still seen...

New Spherix Global Insights research finds rheumatologists estimate 16% of rheumatoid arthritis patients are refractory to treatment, underscoring continued demand for differentiated therapies despite an increasingly crowded market.Exton, PA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- As the Rheumatoid Arthritis (RA) treatment landscape becomes increasingly competitive, rheumatologists are looking to the pipeline for therapies that can offer more than incremental differentiation. New research from Spher

Immunovant (IMVT) has broad diversification with encouraging updates but faces balanced risk/reward